AAP
SVA

Ardsley Advisory Partners’s Sinovac Biotech, Ltd SVA Stock Holding History

Ardsley Advisory Partners’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-25,000
Closed -$180K – 350
2014
Q1 		$180K Buy
+25,000
New +$166K 0.03% 210

Other funds holding SVA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DSA
Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
PRCM
Pine River Capital Management Minnetonka, Minnesota $32.9M AUM 4.47% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Ardsley Advisory Partners's SVA Position: Q2 2014 in Review

Ardsley Advisory Partners sold out of Sinovac Biotech, Ltd (SVA) in Q2 2014, closing a stake of 25,000 shares — an estimated $180K sold.

Ardsley Advisory Partners first reported a position in SVA in Q1 2014 and held it in 1 quarter. The position peaked at $180K in Q1 2014. 50 funds tracked by Wall St. Rank hold SVA as of Q2 2014.

  • Ardsley Advisory Partners reported no remaining Sinovac Biotech, Ltd position as of Q2 2014 after selling out during the quarter.
  • Ardsley Advisory Partners sold 25,000 Sinovac Biotech, Ltd shares in Q2 2014, an estimated $180K.
  • Ardsley Advisory Partners first reported a position in Sinovac Biotech, Ltd in Q1 2014 and held it in 1 quarter.
  • Ardsley Advisory Partners's Sinovac Biotech, Ltd position peaked at $180K in Q1 2014.
  • 50 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q2 2014.

Based on Ardsley Advisory Partners's 13F filing for Q2 2014, filed 14 Aug 2014.